Introduction: The etiology/pathophysiology of preeclampsia remains an enigma. Maternal inflammation (humoral and cellular) is a key factor in the etiology of late-onset preeclampsia (L-PrE). Presepsin is split out from the phagocytes membranes after phagocytosis. It is known as a novel inflammation marker. To our knowledge, this is the first study in literature in English to investigate maternal blood concentrations of presepsin in preeclampsia and healthy pregnant women.
Methods: We examined maternal plasma interleukin-6, presepsin and pentraxin-3 concentrations in pregnant women with ( = 44) and without L-PrE ( = 44). These three inflammatory markers concentrations measured using enzyme-linked immunosorbent assays were compared.
Results: The mean maternal age and gestational age at sampling are similar in the both groups ( ≥ .05). Interleukin-6, presepsin and pentraxin-3 concentrations differed between the groups ( < .05). There was no difference between the three inflammatory markers concentrations in patients with mild (22 patients) and severe (22 patients) preeclampsia in L-PrE ( ≥ .05). A significant discriminative role of interleukin-6, presepsin and pentraxin-3 for presence of L-PrE, with cutoff values of 39.74 pg/mL, 309.88 mg/L and 34.96 ng/mL, respectively, were reported in a ROC curve analysis. When the patients with and without small for gestational age infants (12 patients and 76 patients, respectively) were compared, it was determined that there was no differences between the interleukin-6, but there were differences between the presepsin and pentraxin-3 concentrations ( = .016, = .008, respectively).
Conclusion: Lower concentrations of interleukin-6/presepsin and higher concentrations of pentraxin-3 were associated with the development of preeclampsia. Further investigations of inflammatory/immunity markers in pregnancy are required and may ultimately lead to novel therapeutic approaches to treat complications of pregnancy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14767058.2020.1716718 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Presepsin Does Not Predict Risk of Death in Sepsis Patients Admitted to the Intensive Care Unit: A Prospective Single-Center Study.
Biomedicines
October 2024
Department of Acute Medicine, Medical University of Silesia, 41800 Zabrze, Poland.
: Sepsis is defined as life-threatening organ dysfunction caused by an abnormal host response to infection. The study aimed to evaluate the utility of presepsin (P-SEP) in predicting the risk of death in patients with sepsis at the time of intensive care unit (ICU) admission. : Adult patients were included in the study if they met SEPSIS-3 criteria at ICU admission.
View Article and Find Full Text PDFObjective: To create the prognostic scale based on some biomarkers after thoracic and thoracoabdominal aortic repair.
Material And Methods: We analyzed 114 patients with aortic aneurysm/dissection. The following biomarkers were studied: proadrenomedullin, NT-proBNP, procalcitonin, interleukins 6, 8, 10, tumor necrosis factor, presepsin, highly sensitive troponin I.
Efficacy of proinflamatory cytokines in the clinical and radiograpic outcomes of different primary molar pulpotomy agents: a comperative randomised study featuring a novel biomarker for pulpal diagnosis.
BMC Oral Health
October 2024
Department of Biochemistry, Ataturk University Faculy of Medicine, Erzurum, Turkey.
Background: While the effect of biomaterials covering the pulp tissue is considered in the success of pulpotomy treatment, the level of pulpal inflammation is still very important for treatment success. The aim of this study was to compare IL-6 and IL-8 levels, known as good indicators of pulpal inflammation, with a new biomarker, presepsin, and to evaluate the impact of biomarker levels along with the pulp capping agents used in the treatment on the one-year success of pulpotomy treatment.
Methods: The study included 120 primary second molar teeth with pulpotomy indications from 75 children.
Usability of presepsin, calprotectin, and interleukin 6 in the diagnosis of acute appendicitis.
Biomarkers
November 2024
Department of Biostatistics, Faculty of Medicine, Ataturk University, Erzurum, Turkey.
Article Synopsis
- This study evaluated the effectiveness of three biomarkers (presepsin, calprotectin, and interleukin-6) in diagnosing acute appendicitis and differentiating between complicated and uncomplicated cases.
- Conducted at an emergency department, the research involved 90 participants, split evenly between patients with acute appendicitis and healthy controls, with significant findings for the biomarkers in the appendicitis group.
- The conclusion drawn was that while these biomarkers can aid in diagnosing acute appendicitis, they do not effectively distinguish between complicated and uncomplicated cases.
Role of interleukin 6 polymorphism and inflammatory markers in outcome of pediatric Covid- 19 patients.
BMC Pediatr
October 2024
Pediatric Department, Faculty of Medicine, Minia University, Minia, Egypt.
Background: IL-6 polymorphisms were associated to viral infection outcomes through affection of IL-6 production and it is an early indicator of tissue injury and systemic inflammatory response. The study aimed to determine whether genetic IL-6 polymorphisms, serum interleukin-6 level and inflammatory markers (Presepsin, CXCL-10, C3, and C4) are associated with the prediction of disease severity in pediatric COVID-19 patients and its possible use as a prognostic tool in pediatric patients admitted to hospital.
Methods: This prospective cohort study was conducted on 150 children with COVID-19.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!